News | August 21, 2025
NATCO launches Bosentan Tablets for oral suspension in US with 180-day exclusivity
NATCO holds the first-to-file status for this product and will have 180-day generic drug exclusivity
NATCO holds the first-to-file status for this product and will have 180-day generic drug exclusivity
Macitentan tablets are an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension
TFOS is indicated for the treatment of pulmonary arterial hypertension
Selexipag is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
The company has received five final approvals
This product will be manufactured at Lupin's Nagpur facility in India
Macitentan tablets, 10 mg have an estimated market size of US $ 797 million for twelve months ending Dec 2021 according to IQVIA
The tablets are indicated for the treatment of pulmonary arterial hypertension
Subscribe To Our Newsletter & Stay Updated
